GlaxoSmithKline Czech Republic made a net profit of CZK 125 mil in 2015, up 42.1% when compared to the last year. Total sales reached CZK 4,378 mil, which is down 9.83% when compared to the previous year.
Historically, the company’s net profit reached an all time high of CZK 240 mil in 2011 and an all time low of CZK -7.67 mil in 2006.
In terms of sales, GlaxoSmithKline Czech Republic reached an all time high of CZK 6,186 mil in 2009 and an all time low of CZK 3,161 mil in 2004.
GlaxoSmithKline Czech Republic's net profit has grown -5.49% a year on average in the last five years while sales have increased by -6.62% a year since 2010.
The firm generated its shareholders an average return on invested capital of 9.48% in the last five years.
As far as GlaxoSmithKline Czech Republic's peers are concerned, Roche Czech Republic posted a net profit and sales of CZK 51.0 mil and CZK 5,445 mil in 2015, Bayer Czech Republic generated a net profit of CZK 123 mil (with sales of CZK 4,277 mil) and Amgen Czech Republic netted CZK 35.8 mil (sales of CZK 604 mil).